



INDIANA UNIVERSITY
**MELVIN AND BREN SIMON
 COMPREHENSIVE CANCER CENTER**

Cancer center research at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

ORAL ABSTRACT SESSIONS

Abstract title	IU authors; presenter names are bolded	Date/time	Abstract	Abstract link
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).	Nabil Adra	June 1, 2024; 3 p.m. - 6 p.m. CDT	LBA5000	https://meetings.asco.org/abstracts-presentations/234511
Risk prediction model for taxane-induced peripheral neuropathy (TIPN) in patients with early-stage cancer receiving taxane therapy: SWOG S1714.	Bryan P. Schneider	June 2, 2024; 8 a.m. - 11 a.m. CDT	12005	https://meetings.asco.org/abstracts-presentations/232442
Primary outcomes of the enhanced, EHR-facilitated cancer symptom control (E2C2) cluster-randomized, stepped wedge, pragmatic trial.	Kurt Kroenke	June 2, 2024; 8 a.m. - 11 a.m. CDT	LBA12006	https://meetings.asco.org/abstracts-presentations/232437
A multicenter analysis evaluating educational resources utilized by hematology/oncology fellows (HOF).	Fadi Taza	June 3, 2024; 9:45 a.m. - 11:15 a.m. CDT	9003	https://meetings.asco.org/abstracts-presentations/231743
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.	Tarah J. Ballinger , Kathy Miller, Bryan P. Schneider	June 3, 2024; 3 p.m. - 6 p.m. CDT	LBA503	https://meetings.asco.org/abstracts-presentations/232433

EDUCATION SESSIONS/PANELS

Session title	Panelist	Date/time	Session detail	Session link
Patient-Centered Care and Advances in the Treatment of Testis and Penile Cancer: "Long-Term Survivorship and Treatment Deintensification in Testis Cancer"	Lois Travis	May 31, 2024, 2:45 p.m. - 4:00 p.m. CDT	Education session	https://meetings.asco.org/2024-asco-annual-meeting/15717?presentation=228467#228467
A Multidisciplinary Approach to Managing the Toxicities Associated With Renal Cell Carcinoma Therapy	Suparna Chandra Clasen	June 3, 2024; 4:45 p.m. - 5:45 p.m. CDT	Case-based panel	https://meetings.asco.org/2024-asco-annual-meeting/15735?presentation=228520#228520

POSTER SESSIONS

Abstract title	IU authors; presenter names are bolded	Date/time	Abstract number, poster number	Abstract link
Serial testing to assess cognitive function in patients with cancer being treated with immunotherapy.	Shobha Shahani , Ali Ajrouch, Nasser Hanna	June 1, 2024; 9 a.m. - 12 p.m. CDT	Abstract #TPS1644; Poster #512a	https://meetings.asco.org/abstracts-presentations/238283
Disparities in breast cancer prevention initiatives at a comprehensive cancer center: Who are we serving?	Tarah Ballinger	June 1, 2024; 9 a.m. - 12 p.m. CDT	Abstract #1615; Poster #486	https://meetings.asco.org/abstracts-presentations/233764
A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies.	Shadia Jalal	June 1, 2024; 9 a.m. - 12 p.m. CDT	Abstract #3112; Poster #257	https://meetings.asco.org/abstracts-presentations/234082
Facilitating adaptive coping with fear of recurrence among breast cancer survivors: Feasibility and acceptability outcomes from a three-arm randomized controlled trial.	Shelley Johns , Kathy Miller	June 1, 2024; 9 a.m. - 12 p.m. CDT	Abstract #1630; Poster #501	https://meetings.asco.org/abstracts-presentations/239696
Exploring health disparities in prostate cancer through circulating tumor DNA analysis.	Samaneh Maleknia , Nabil Adra, Reza Shahbazi	June 1, 2024; 9 a.m. - 12 p.m. CDT	Abstract # 1603; Poster #474	https://meetings.asco.org/abstracts-presentations/233719
Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.	Greg Durm	June 1, 2024; 9 a.m. - 12 p.m. CDT	Abstract #2524; Poster #3	https://meetings.asco.org/abstracts-presentations/233884
A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.	Mateusz Opyrchal	June 1, 2024; 9 a.m. - 12 p.m. CDT	Abstract #2623; Poster #102	https://meetings.asco.org/abstracts-presentations/233991
Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma.	Melissa Bear	June 1, 2024; 1:30 p.m. - 4:30 p.m. CDT	Abstract #10033; Poster #400	https://meetings.asco.org/abstracts-presentations/230983

Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.	Melissa Bear	June 1, 2024; 1:30 p.m. – 4:30 p.m. CDT	Abstract #10032; Poster #399	https://meetings.asco.org/abstracts-presentations/230982
Genomic signature analysis and survival outcomes in cholangiocarcinoma (CCA) using oncology research information exchange network (ORIEN) database.	Anita Turk, Ashiq Masood	June 1, 2024; 1:30 p.m. – 4:30 p.m. CDT	Abstract #4101; Poster #81	https://meetings.asco.org/abstracts-presentations/234270
QUIC: Phase 2 study of gemcitabine, cisplatin, quercetin, and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.	Anita Turk	June 1, 2024; 1:30 p.m. – 4:30 p.m. CDT	Abstract #TPS4195; Poster #167b	https://meetings.asco.org/abstracts-presentations/239048
Longitudinal evaluation of circulating tumor DNA (ctDNA) as a prognostic biomarker to detect minimal residual disease (MRD) in testicular cancer.	Rebecca Hassoun , Clint Cary, Timothy Masterson, Jennifer King, Lawrence Einhorn, Nabil Adra	June 2, 2024; 9 a.m. – 12 p.m. CDT	Abstract #5034; Poster #352	https://meetings.asco.org/abstracts-presentations/234447
Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse.	Ahmed Bilal Khalid , Tareq Salous, Clint Cary, Timothy Masterson, Lawrence Einhorn, Nabil Adra, Jennifer King	June 2, 2024; 9 a.m. – 12 p.m. CDT	Abstract #5035; Poster #353	https://meetings.asco.org/abstracts-presentations/234453
Management of progressive brain metastases in patients (pts) with relapsed germ-cell tumor (GCT) treated with salvage high-dose chemotherapy (HDCT).	Jennifer King , Rafat Abonour, Tareq Salous, Nasser Hanna, Lawrence Einhorn, Nabil Adra	June 2, 2024; 9 a.m. – 12 p.m. CDT	Abstract #5036; Poster #354	https://meetings.asco.org/abstracts-presentations/234458
Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma.	Clint Cary	June 2, 2024; 9 a.m. – 12 p.m. CDT	Abstract #5037; Poster #355	https://meetings.asco.org/abstracts-presentations/238914
Long term cardiovascular adverse outcomes in testicular cancer survivors: Real-world U.S. population-based study.	Nabil Adra	June 2, 2024; 9 a.m. – 12 p.m. CDT	Abstract #5042; Poster #448	https://meetings.asco.org/abstracts-presentations/234506
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage I, HR+, HER2-, RS ≤18 breast cancer.	Richard Zellars	June 2, 2024; 9 a.m. – 12 p.m. CDT	Abstract #TPS622; Poster #208b	https://meetings.asco.org/abstracts-presentations/238244
A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC).	Nabil Adra	June 2, 2024; 9 a.m. – 12 p.m. CDT	Abstract #4542; Poster #237	https://meetings.asco.org/abstracts-presentations/234391
Unraveling the gene expression signatures with associated clinical outcomes in papillary renal cell carcinoma.	Jennifer King	June 2, 2024; 9 a.m. – 12 p.m. CDT	Abstract #4558; Poster #253	https://meetings.asco.org/abstracts-presentations/232028
Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587).	Jennifer King	June 2, 2024; 9 a.m. – 12 p.m. CDT	Abstract #TPS4614; Poster #305b	https://meetings.asco.org/abstracts-presentations/238451
Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC O30.	Kathy Miller	June 2, 2024; 9 a.m. – 12 p.m. CDT	Abstract #555; Poster #147	https://meetings.asco.org/abstracts-presentations/233441
RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).	Anna Maria Storniolo	June 2, 2024; 9 a.m. – 12 p.m. CDT	Abstract #530; Poster #122	https://meetings.asco.org/abstracts-presentations/233453
Improved survival for myeloid malignancy patients receiving thiotepa/cyclophosphamide (TT/Cy) versus total body irradiation/cyclophosphamide (TBI/Cy) conditioning and allogeneic stem cell transplantation.	Cydney Nichols , Jennifer Schwartz, Michael Robertson, Rafat Abonour	June 3, 2024; 9 a.m. – 12 p.m. CDT	Abstract #6555; Poster #114	https://meetings.asco.org/abstracts-presentations/232600
Comparison of the clinical and genomic profiles of endometrial cancer in Appalachian and non-Appalachian patients.	Lisa Landrum	June 3, 2024; 9 a.m. – 12 p.m. CDT	Abstract #5591; Poster #462	https://meetings.asco.org/abstracts-presentations/234550
Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with dostarlimab plus chemotherapy in the RUBY trial.	Lisa Landrum	June 3, 2024; 9 a.m. – 12 p.m. CDT	Abstract #5606; Poster #477	https://meetings.asco.org/abstracts-presentations/234678
Thiotepa/cyclophosphamide (TT/Cy) preparative regimen for patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation.	Cydney Nichols , Jennifer Schwartz, Michael Robertson, Rafat Abonour	June 3, 2024; 9 a.m. – 12 p.m. CDT	Abstract #6556; Poster #114	https://meetings.asco.org/abstracts-presentations/232610
Comprehensive molecular characterization of thymic epithelial tumors.	Patrick Loehrer, Rohan Maniar	June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT	Abstract #8113; Poster #375	https://meetings.asco.org/abstracts-presentations/232836
Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: 2024 update of a model for remote clinical trial participation.	Brenna McDonald	June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT	Abstract # TPS12147; Poster #275b	https://meetings.asco.org/abstracts-presentations/238569
A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.	Misty Shields, Shadia Jalal	June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT	Abstract #TPS8129; Poster #384a	https://meetings.asco.org/abstracts-presentations/238527
A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.	Greg Durm , Nasser Hanna	June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT	Abstract #TPS8118; Poster #378b	https://meetings.asco.org/abstracts-presentations/238538

SPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers.	Kurt Kroenke	June 3, 2024; 9 a.m. – 12 p.m. CDT	Abstract #11108; Poster #303	https://meetings.asco.org/abstracts-presentations/233216
Proactive, automated monitoring of uncontrolled symptoms in prostate cancer survivors across the cancer control continuum.	Kurt Kroenke	June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT	Abstract #12079; Poster #208	https://meetings.asco.org/abstracts-presentations/231364
Symptom burden in adolescents and young adults with cancer: A subgroup analysis of the enhanced, EHR-facilitated cancer symptom control (E2C2) trial.	Kurt Kroenke	June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT	Abstract #12065; Poster #194	https://meetings.asco.org/abstracts-presentations/233400
Formation and evaluation of the ASCO medical education community of practice (Med Ed CoP).	Jennifer Schwartz	June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT	Abstract #9022; Poster #11	https://meetings.asco.org/abstracts-presentations/232898
A meta-analysis GWAS of taxane-induced peripheral neuropathy in patients with breast cancer.	Bryan P. Schneider	June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT	Abstract #12089; Poster #218	https://meetings.asco.org/abstracts-presentations/231310

PUBLICATION ONLY ABSTRACTS

Abstract title	IU authors	Abstract	Abstract link
Risk factors associated with liver cancer in all US participants.	Jing Su	Abstract #e16276	https://meetings.asco.org/abstracts-presentations/236031
Clinical features, genomic alterations, and survival outcomes for variant histology urothelial carcinoma.	Bryan Schneider, Nabil Adra, Jennifer King	Abstract # e16549	https://meetings.asco.org/abstracts-presentations/232022
Real-world clinical and toxicity outcomes in older Veterans with metastatic renal cell carcinoma (mRCC) treated with front-line systemic therapy.	Jennifer King	Abstract # e16525	https://meetings.asco.org/abstracts-presentations/231949
Unraveling the role of CTLA-4 variants in acute kidney injury after ICI treatments.	Jing Su	Abstract # e14682	https://meetings.asco.org/abstracts-presentations/235466
Outcomes in STK11-, KEAP1-, and KRAS-mutant lung squamous cell carcinoma (LSCC) with use of immune checkpoint inhibitors (ICIs).	Julian A. Marin-Acevedo, Misty Shields, Nasser Hanna	Abstract # e20504	https://meetings.asco.org/abstracts-presentations/232267
Prescription drug, healthcare utilization, and lost earnings cost of behavioral interventions for fear of cancer recurrence in breast cancer survivors.	Kathy Miller, Shelley Johns	Abstract e24095	https://meetings.asco.org/abstracts-presentations/231436
The impact of smoking status on genomic profile in patients with renal cell carcinoma.	Bryan Schneider, Theodore Logan, Nabil Adra, Tareq Salous, Jennifer King	Abstract # e16521	https://meetings.asco.org/abstracts-presentations/231996
Updated safety and efficacy analysis comparing elderly vs nonelderly patients treated with consolidation nivolumab or nivolumab plus ipilimumab after chemoradiation for unresectable stage III NSCLC from the BTCRC LUN 16-081 clinical trial.	Nasser Hanna, Greg Durm	Abstract # e13770	https://meetings.asco.org/abstracts-presentations/237348
Genomic alterations and clinical outcomes in patients with non-clear cell RCC: Indiana University experience.	Fadi Taza, Bryan Schneider, Tareq Salous, Theodore Logan, Nabil Adra, Jennifer King	Abstract # e16506	https://meetings.asco.org/abstracts-presentations/231914
Xerostomia and ocular dryness as predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.	Tareq Salous, Jennifer King, Nabil Adra	Abstract # e17028	https://meetings.asco.org/abstracts-presentations/236097
Neuroendocrine features in small cell lung cancer (SCLC) and associations with platinum-sensitivity, metastatic tropism, and overall survival.	Julian A. Marin-Acevedo, Misty Shields, Mya Tran	Abstract # e20113	https://meetings.asco.org/abstracts-presentations/238069
The survival benefits and the risk of severe renal injury of immune checkpoint inhibitors in patients with cancer: The real-world evidence from the National Clinical Cohort Collaborative (N3C).	Tyler Shugg, Shadia Jalal, Jing Su	Abstract # e24142	https://meetings.asco.org/abstracts-presentations/231447
Characterization of novel compounds that directly bind to and inactivate the HPV E6 protein for treatment of HPV-associated cervical and oropharyngeal cancers.	Anne Rietz, Elliot Androphy	Abstract # e15122	https://meetings.asco.org/abstracts-presentations/235563